Health & Biotech
Check Up: Rhythm (ASX:RHY) plans US expansion, the US$1.5b dog dermatitis market and data dumps drive stocks down
Health & Biotech
ASX health stocks: AusCann (ASX:AC8) up 5pc after asking for approval of cannabis-based canine drug
Health & Biotech
Medibis raises funds for research and cultivation facility, sets eyes on huge medicinal cannabis market
Health & Biotech
Dimerix shares up 25pc in July as FDA confirms Phase 3 study design for FSGS kidney treatment
Health & Biotech
ASX health stocks today: AdAlta (ASX:1AD) leads after successful Phase I study
Health & Biotech
Dr Boreham’s Crucible: Can Lumos (ASX:LDX) light up the US with FDA approval?
Health & Biotech
Wellnex Life rounds out first week after relisting on a high note
Health & Biotech
Incannex secures complete supply chain solution for its anti-inflammatory multi-use drug
Health & Biotech
ScoPo’s Powerplays: ASX biotech IPOs show ‘money is out there’; Virtus to benefit from rise in IVF
Health & Biotech
Creso Pharma welcomes Senate Democrats’ bid to legalise cannabis
Health & Biotech
Weed Week: The CanCoin, cannabis tourism, and record medicinal product sales in Australia
Health & Biotech
These two ASX brain health stocks, boosted by FDA’s approval of Adulhelm, are kicking off clinical trials
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.